News
Could bats hold the key to human longevity?

A new research project is underway to explore whether bats could hold the secret to health and longevity.
A team led by Professor Emma Teeling, Full Professor of Zoology at University College Dublin (UCD), has won a European Research Council (ERC) Synergy grant of almost €12 million (£10.4 million) to explore the question.
The UCD researcher has pioneered global research into the development of bats as new models for healthy ageing and disease tolerance.
Professor Teeling will lead the groundbreaking Synergy project ’BATPROTECT’, involving a team of 22 researchers – including leading experts from Germany and Singapore.
The project is expected to achieve a step-change in our understanding of bats’ extended health span and disease resistance.
Professor Teeling said: “We have just been given the most extraordinary opportunity to finally harness the amazing adaptations of bats and provide new ways to slow down human ageing and disease resistance.
“This ERC Synergy grant has enabled us to unite the fields of bat biology, virology, immunology, genomics and gerontology, across Europe and Asia, in order to achieve our goals.
“We are thrilled and excited to work together and uncover how we can live longer, healthier lives by learning from bats.”
The challenges posed by ageing and infectious diseases in our societies are associated with significant medical, financial, and emotional burdens.
Previous research has struggled to offer solutions to increase human health span and protect against the harmful effects of infections.
However, bats as the only flying mammals have addressed both of these problems.
Even though the mammals serve as hosts for numerous dangerous viruses, they usually don’t show symptoms of viral infections thanks to their unique immune system adaptations.
They also have exceptional longevity and show little-to-no signs of any age related diseases.
The main objective of the research is to make significant advancements in our understanding of the specific genetic and biochemical factors within bats that are responsible for their ability to live longer, healthier lives and resist diseases.
Uncovering these molecular mechanisms has the potential to open up new possibilities for improving human health and disease outcomes.
The project brings together world-leading researchers in bat biology, immunology, genomics and gerontology.
Ultimately, the research aims to deepen our knowledge of how bats manage to stay healthy and resist diseases, potentially paving the way for future therapeutics.
UCD Interim Vice-President for Research, Innovation and Impact, Professor Helen Roche said: “We are immensely proud of Professor Teeling and Dr Harnett in their achievement.
“UCD is ranked number one in Ireland and 23rd among higher education institutions in Europe for Horizon Europe funding.
“These awards really exemplify the excellence of our outstanding researchers, who are building important international collaborations to address global challenges.
“I congratulate the winners and look forward to following their exciting work.”
ERC President Professor Maria Leptin added: “Congratulations to all the winners!
“The selected projects are shining examples of audacious scientific thinking, and I eagerly await the outcomes of these collaborative endeavours.”
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.













